Skip to content

Dose finding and constipation effect by the intake of a newly oligomeric condensation of lactic acids, GL-1708: a randomized, double blind, placebo-controlled study

Dose finding and constipation effect by the intake of a newly oligomeric condensation of lactic acids, GL-1708: a randomized, double blind, placebo-controlled study - Dose finding and constipation effect by the intake of a newly oligomeric condensation of lactic acids, LAC

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000030449
Enrollment
60
Registered
2018-04-30
Start date
2017-12-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healty adult

Interventions

Ingestion of capsules containing a newly oligo lactic acids, LAC, daily for consecutive 4 weeks Ingestion of placebo(capsules without a newly oligo lactic acids) daily for consecutive 4 weeks

Sponsors

Kands R&D Corporation
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) An age 30 years or older and up to 60 years, the age shall be the date of informed consent acquisition) 2) Subjects with constipation (functional constipation) whose stool frequency is 10 or less in 2 weeks 3) Subjects who are judged as suitable for the study by the investigotor 4) Those who received sufficient explanation about the purpose of this study and agree to subject in an informed consent

Exclusion criteria

Exclusion criteria: 1) A medical history of severe disorders, which affects absorption, metabolism, excretion in the digestive tract, heart, liver, thyroid gland and kidney, or those subjects who have difficulty in participating in this study of their past medical history 2) Gastrectomy, gastrointestinal sutures, who have major surgery history affects absorption in the gastrointestinal tract site such as intestinal resection 3) Those who have hypersensitivity to drugs or idiosyncrasies 4) Those who have ever suffered from a physical disorder by ingesting a commercially available supplement 5) Alcohol or drug addicts 6) Pregnancy or women of childbearing potential, who wish to become pregnant during lactation or test period 7) Those who are participating in other clinical trials at the start of this study 8) Those who participated in clinical trials of medicines within 16 weeks before this study, or human examination of health food within 8 weeks 9) Those who took medical prescription medicines such as an intestinal tract or the like, which have an effect on constipation treatment etc. within one week before the start of the study 10) Those who collected 400 mL or more of whole blood within 12 weeks before the start of the test 11) In addition, those judged unsuitable as subjects by investigators

Design outcomes

Primary

MeasureTime frame
This study aim to evaluate the effects of ingestion of food containing LAC for 4 weeks on constipation effect in subjects with bowel movement slower.

Secondary

MeasureTime frame
Efficacy

Countries

Japan

Contacts

Public ContactShigeru Taguchi

Kands R&D Corporation Bord director

shige-taguchi@kkd.biglobe.ne.jp042-372-5169

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026